{
  "trial_id": "NCT03502148",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, ECOG performance status, tumor size, tumor location, renal function (creatinine clearance), organ function (safety labs), prior systemic chemotherapy, presence of concurrent malignancy, history of exposure to investigational agents, allergy or hypersensitivity to platinum-containing agents, infection status, pregnancy status, contraception use, ability to provide informed consent, ability to return for follow-up visits.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "ECOG Performance Status",
          "ECOG performance status"
        ],
        [
          "Adequate renal function as demonstrated by renal creatinine clearance",
          "renal function (creatinine clearance)"
        ],
        [
          "Adequate organ function as assessed by safety labs",
          "organ function (safety labs)"
        ],
        [
          "Systemic chemotherapy for the treatment of SCC of the head and neck less than 2 years prior to screening",
          "prior systemic chemotherapy"
        ],
        [
          "Concurrent documented malignancy, with the exception of localized SCC of the skin",
          "presence of concurrent malignancy"
        ],
        [
          "Exposure to any investigational agent within 3 months prior to screening",
          "history of exposure to investigational agents"
        ],
        [
          "Known allergy or hypersensitivity to platinum-containing agents",
          "allergy or hypersensitivity to platinum-containing agents"
        ],
        [
          "Active, uncontrolled infection requiring systemic therapy",
          "infection status"
        ],
        [
          "Known or suspected pregnancy, planned pregnancy or lactation",
          "pregnancy status"
        ],
        [
          "Agree to use effective contraception for 30 days after the last dose of study drug",
          "contraception use"
        ],
        [
          "Willing and able to provide written informed consent",
          "ability to provide informed consent"
        ],
        [
          "Able to return to the study site for treatment and follow-up visits as defined in the protocol",
          "ability to return for follow-up visits"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "tumor size",
        "tumor location"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Tumor Size, ECOG Performance Status, Renal Function (Creatinine Clearance), Organ Function (Safety Labs), Contraception Use,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Tumor Size",
        "ECOG Performance Status",
        "Renal Function (Creatinine Clearance)",
        "Organ Function (Safety Labs)",
        "Contraception Use"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Tumor size, Tumor location, Histological grade, Prior treatment, Renal creatinine clearance, Organ function.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "ECOG Performance Status",
        "Tumor size",
        "Tumor location",
        "Histological grade",
        "Prior treatment",
        "Renal creatinine clearance",
        "Organ function."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG Performance Status, tumor size, tumor location, histological grade, renal creatinine clearance, organ function (as assessed by safety labs), prior systemic chemotherapy, prior radiation therapy, presence of comorbidities.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "tumor size",
        "tumor location",
        "histological grade",
        "renal creatinine clearance",
        "organ function (as assessed by safety labs)",
        "prior systemic chemotherapy",
        "prior radiation therapy",
        "presence of comorbidities"
      ]
    }
  }
}